Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IM CAB LA
CAB LA · 6 trials · 1 indication
A virologic suppression is defined by HIV-1 RNA less than (\<) 50 copies (c)/mL.
Relevant characteristics of new HIV infections will be assessed, including presence of viral resistance to CAB.
AIM is a four item survey that assessed the acceptability of an implementation process. The staff study participants were asked to indicate how much they agreed or disagreed with each of the 4 items in the AIM based on their current experiences with implementing the CAB + RPV injection treatment on a five point rating scale (1=completely disagree to 5=completely agree). The AIM total score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Baseline is defined as the latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value.
AIM is a four item survey that assessed the acceptability of an implementation process. The staff study participants were asked to indicate how much they agreed or disagreed with each of the 4 items in the AIM based on their current experiences with implementing the CAB + RPV injection treatment on a five point rating scale (1=completely disagree to 5=completely agree). The AIM total score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Baseline is defined as the latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value.
AIM is a four item survey that assessed the acceptability of an implementation process. The participants were asked about their impressions of the CAB LA + RPV LA injection treatment for treating HIV on a five point rating scale (1=completely disagree to 5=completely agree). The AIM total score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Baseline is defined as the latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value.
AIM is a four item survey that assessed the acceptability of an implementation process. The participants were asked about their impressions of the CAB LA + RPV LA injection treatment for treating HIV on a five point rating scale (1=completely disagree to 5=completely agree). The AIM total score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Baseline is defined as the latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value.
IAM is a four item survey that assessed the appropriateness of an implementation process. The staff study participants were asked to indicate how much they agreed or disagreed with each of the 4 items in the IAM based on their current experiences with implementing the CAB + RPV injection treatment on a five point rating scale (1=completely disagree to 5=completely agree). The IAM total score ranges from 1 to 5 with 1 indicating the least appropriateness and 5 the most appropriateness. Baseline is defined as the latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value.
IAM is a four item survey that assessed the appropriateness of an implementation process. The staff study participants were asked to indicate how much they agreed or disagreed with each of the 4 items in the IAM based on their current experiences with implementing the CAB + RPV injection treatment on a five point rating scale (1=completely disagree to 5=completely agree). The IAM total score ranges from 1 to 5 with 1 indicating the least appropriateness and 5 the most appropriateness. Baseline is defined as the latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value.
IAM is a four item survey that assessed the appropriateness of an implementation process. The participants were asked to indicate how much they agreed or disagreed with each of the 4 items in the IAM based on their current experiences with implementing the CAB + RPV injection treatment on a five point rating scale (1=completely disagree to 5=completely agree). The IAM total score ranges from 1 to 5 with 1 indicating the least appropriateness and 5 the most appropriateness. Baseline is defined as the latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value.
IAM is a four item survey that assessed the appropriateness of an implementation process. The participants were asked to indicate how much they agreed or disagreed with each of the 4 items in the IAM based on their current experiences with implementing the CAB + RPV injection treatment on a five point rating scale (1=completely disagree to 5=completely agree). The IAM total score ranges from 1 to 5 with 1 indicating the least appropriateness and 5 the most appropriateness. Baseline is defined as the latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value.
FIM is a four item survey that assessed the feasibility of an implementation process. The staff study participants were asked to indicate how much they agreed or disagreed with each of the 4 items in the FIM based on their current experiences with implementing the CAB + RPV injection treatment on a five point rating scale (1=completely disagree to 5=completely agree). The FIM total score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Baseline is defined as the latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value.
FIM is a four item survey that assessed the feasibility of an implementation process. The staff study participants were asked to indicate how much they agreed or disagreed with each of the 4 items in the FIM based on their current experiences with implementing the CAB + RPV injection treatment on a five point rating scale (1=completely disagree to 5=completely agree). The FIM total score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Baseline is defined as the latest pre-treatment assessment with a non-missing value, including those from unscheduled visits. Change from Baseline value is defined as post-dose value minus Baseline value.
CAB trough concentrations are evaluated at or above the target of 1.05 μg/mL for men and 1.39 μg/mL for women, once steady state has been achieved, but no earlier than Month 13 of the study.
Percentage of participants with HIV-1 RNA \>=50 c/mL as per FDA snapshot algorithm at Month 12 was assessed to demonstrate the antiviral activity of CAB LA+RPV LA Q2M and DTG + RPV regimen in HIV-1 infected antiretroviral therapy (ART) experienced participants. The HIV-1 RNA \>=50 c/mL per Snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the 12 months analysis visit window.
| Arm | Type | Description |
|---|---|---|
| CAB LA + RPV LA Group | EXPERIMENTAL | Participants receive initial injections at Day 1 and Month 1, followed by maintenance injections every 2 months for up to 24 months. |
| Oral ART Control Group | ACTIVE_COMPARATOR | Participants continue to take their current oral ART for 6 months, including a final dose at their first injection visit. |
| CAB LA 600 mg (Q8W) | EXPERIMENTAL | All enrolled participants have previously received CAB LA as part of the HPTN 083 and HPTN 084 parent studies or their sub-studies. Participants will continue receiving CAB LA 600 mg via gluteal intramuscular (IM) injection. |
| Subjects with HIV infection | EXPERIMENTAL | HIV-infected subjects receiving CAB LA+RPV LA will be included in this arm. |
| CAB Group | EXPERIMENTAL | Participants receive lead-in injections comprising cabotegravir LA during month one and injections of a new formulation of CAB LA at Month 3, Month 5 and every 4 months thereafter to Month 29. |
| CAB LA + RPV LA Q2M | EXPERIMENTAL | Eligible participants from LAI116482 (NCT01641809 \[LATTE\]) study who were administered oral CAB 30 milligrams (mg) plus RPV 25 mg and who successfully completed Week 300 received their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections were administered 1 month after initial loading dose, with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Participants continued to receive the treatment until the study intervention was locally approved and commercially available. Participants who received at least one dose of CAB LA and/or RPV LA and discontinued the CAB LA + RPV LA regimen for any reason entered a 52-week long-term follow-up (LTFU) Phase. |
| DTG + RPV | EXPERIMENTAL | Eligible participants from LAI116482 (NCT01641809 \[LATTE\]) study who were administered oral CAB 30 mg plus RPV 25 mg and who successfully completed Week 300 received their first dose of the Dolutegravir (DTG) 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12 in the current study. These participants were not eligible for the LTFU phase. |
| LTFU: CAB LA+RPV LA Q2M Group | EXPERIMENTAL | This group included the participants who received at least one dose of CAB LA and/or RPV LA and discontinued the CAB LA + RPV LA regimen for any reason before end of Maintenance Period. The participants entered a 52-week LTFU period. |
| Name | Type | Description |
|---|---|---|
| CAB LA + RPV LA | DRUG | Intramuscular injection administered monthly for first 2 initiation doses then every 2 months. |
| Oral ART | DRUG | Oral medication provided to participants by the site/their regular healthcare professional (HCP) as part of their standard of care (SOC) treatment. |
| CAB LA | DRUG | Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W). |
| CAB LA+RPV LA | DRUG | Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection. |
| New formulation of CAB LA | DRUG | Injections administered IM gluteal. |
| RPV LA | DRUG | Administered RPV LA (900 mg), Q2M, as intramuscular injection. |
| RPV | DRUG | Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12 |
| DTG | DRUG | Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12. |
| CAB ULA | DRUG | CAB ULA injection will be administered |
Inclusion Criteria: * Age 1\. Aged \>=12 years and \>=35 kg (at the time of obtaining informed consent). * Type of Participant and Disease Characteristics 2.HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prio...
Top 20 of 28 competitors
CAB LA, also known as cabotegravir long-acting, is used for HIV infections. It is being studied as a pre-exposure prophylaxis (PrEP) to prevent HIV acquisition and as a treatment for people with detectable HIV-1 when combined with rilpivirine. The drug is administered intramuscularly and is currently in clinical development.
CAB LA is a small molecule that targets the HIV integrase enzyme. By inhibiting integrase, it blocks the integration of viral DNA into human host cells, preventing HIV from replicating. This mechanism underlies its use in both HIV prevention and treatment regimens.
CAB LA is developed by GSK plc, which trades under the ticker GSK. The company is conducting multiple clinical trials to evaluate the drug's effectiveness in HIV prevention and treatment, including long-acting formulations for extended dosing intervals.
CAB LA is in Phase 3 clinical development for HIV infections. It is an investigational drug and has not been approved by regulatory authorities. The Phase 3 trials are evaluating its use as PrEP and for treatment in people with detectable HIV-1.
CAB LA is being studied in several clinical trials, including NCT06134362, a Phase 3 long-term follow-up for PrEP with 2,996 participants, and NCT06694805, a Phase 3 study in people with detectable HIV-1 with 326 participants. Other trials include NCT06741397 and NCT06786520.
CAB LA is the same as CAB LA + RPV LA, which is a combination of cabotegravir long-acting and rilpivirine long-acting. This combination is being studied for HIV treatment, while CAB LA alone is evaluated for HIV prevention as PrEP.